1. Home
  2. AGI vs CORT Comparison

AGI vs CORT Comparison

Compare AGI & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alamos Gold Inc.

AGI

Alamos Gold Inc.

HOLD

Current Price

$34.12

Market Cap

15.8B

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$118.64

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGI
CORT
Founded
2003
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8B
9.7B
IPO Year
2002
2001

Fundamental Metrics

Financial Performance
Metric
AGI
CORT
Price
$34.12
$118.64
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$51.50
★ $96.50
AVG Volume (30 Days)
★ 2.8M
840.0K
Earning Date
04-29-2026
04-30-2026
Dividend Yield
★ 0.28%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.09
Revenue
N/A
★ $761,407,000.00
Revenue This Year
$59.50
$26.08
Revenue Next Year
$14.28
$26.98
P/E Ratio
★ $34.21
$1,254.89
Revenue Growth
N/A
★ 12.79
52 Week Low
$27.05
$28.66
52 Week High
$55.41
$126.38

Technical Indicators

Market Signals
Indicator
AGI
CORT
Relative Strength Index (RSI) N/A 48.93
Support Level N/A $108.25
Resistance Level N/A $124.30
Average True Range (ATR) 0.00 5.11
MACD 0.00 -0.49
Stochastic Oscillator 0.00 34.79

Price Performance

Historical Comparison
AGI
CORT

About AGI Alamos Gold Inc.

Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has three operating segments being Young-Davidson, Island Gold District's operation operates in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Island Gold District mines.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: